Ruti Aga: Six Years Suspended, Two Years Sanctioned — and a Forged Prescription That Ended a Marathon Career

10 September. The date appears twice in the Athletics Integrity Unit (AIU) statement — once as the start of the provisional suspension, once as the start of a six-year ban. Ruti Aga, Ethiopian marathoner, 32 years old. The arithmetic is flat: two years for the presence of a prohibited substance, four years for tampering with the investigation. Total, six.

Not two. Six.

I look at the addition before I look at the story. And this addition does not sit where it should. The East African road-racing cases that draw six years usually involve anabolic steroids, EPO, or blood manipulation. This one does not. Methylprednisolone — the substance the entire case rests on — is not a steroid. It is a glucocorticoid. On the WADA Prohibited List it sits in class S9, not S1. And S9 substances are prohibited in-competition only, by injection, oral or rectal routes.

The first pass looked ordinary; the second pass found the pattern. The real story is not the substance. The real story is the paper.

What the case actually is

According to the AIU statement, Aga's sample was collected after she won a half marathon in China in March and returned an adverse finding for methylprednisolone. Her explanation was that the drug had been taken to treat a knee injury. The investigation established that the clinic whose prescription was submitted does not exist; that the "doctor" who wrote it was a family member with no medical registration; and that he claimed to have used an "old prescription pad from a former workplace" which that clinic explicitly disowned.

Three verification failures, not one. The document was false, the signatory was unregistered, and the pad belonged to someone else.

Aga's record before this case was real. She won the 2026 Tokyo Marathon. She finished second at three World Marathon Majors. She finished second in Berlin in 2026. A 2:18–2:20 class runner with her name written on Major podiums.

The AIU issued its statement on a Thursday. Both the ban and the provisional suspension were dated from 10 September.

Two and four: what the arithmetic says

Why six years is the real technical question.

Under the WADA Code, the baseline sanction for a presence violation is four years, reducible to two where the substance is a Specified Substance and deliberate cheating is not established. Methylprednisolone is a Specified Substance. She received two years — meaning the panel found no proven intent to enhance performance.

The standard Code sanction for tampering is four years. She received four. The addition closes.

What the addition does not say is this: the panel refused the "no significant fault" mitigation. With genuine medical records, a real clinic's prescription, and a documented administration date and route, the presence charge could have been argued far lower — and the tampering charge would never have existed.

I do not write the number until I can rebuild the number. Here it rebuilds, and it points to one thing: the sanction did not come from the substance. It came from the paper.

The calendar and the in-competition window

A road race's testing window opens at 23:59 on the night before the race. If a runner takes a glucocorticoid injection into the knee three or four days out and residue remains in the sample, that is a violation — however legitimate the treatment was.

There were two legal routes here. One: hold or apply for a TUE. Two: observe WADA's route-specific washout period so that residue clears by race day. Had either been followed, this case would not exist.

This needs stating plainly, because most reports are getting the word wrong. Calling methylprednisolone a "prohibited steroid" is technically incorrect. It is a glucocorticoid, class S9, prohibited in-competition only. That distinction shapes the direction of the sanction, not merely the vocabulary.

Which is why Aga's defence pathway existed. She closed it with a forged prescription.

The empty clinic: a system signal

Reaching for a forged prescription does not mean the drug was never taken. Knee pathology is one of the most common load-bearing failures in marathoners, and treating it with a steroid injection is standard sports-medicine practice. What is missing is any recorded evidence of that treatment.

An athlete whose medical team contains not one credentialed physician gets caught exactly here. This is not one person's lapse; it is a network's gap.

One more thing sits in the AIU file: the four-year tampering sanction. Note where that charge came from — an interview. From statements made under questioning. Language and translation conditions in AIU interviews with Ethiopian athletes have been a recurring point of contention. That does not make the sanction right or wrong, but it belongs on the record, because it is the least examined part of this file.

What has not been written down still counts

The statement does not say whether the March race result and prize money were annulled. Standard practice is that the competition at which the sample was collected is automatically disqualified. That means the half marathon win, its prize money, and any ranking points accrued after it are all out of the ledger.

The 2026 Tokyo title is not automatically affected. The violation is anchored to the March race; earlier results stand unless prior use is established.

The part nobody is writing: the payroll

For Ethiopian and Kenyan marathoners, China's label-race circuit is a separate economy. Between Majors, these races pay appearance fees, build deep elite fields, and provide low-risk income. For a 2:18 runner the model works: few races, large fee each.

The problem is that those same races are now the AIU's most productive testing ground. Where the money is dense, the samples are dense. The appearance-fee economy and the testing economy are colliding on the same track.

The counter-question: six years for a drug that does not build endurance

Now the part that is not being argued.

There is no solid evidence that glucocorticoids improve endurance performance. They reduce swelling, they reduce pain — meaning they mask injury, they do not add speed. This is performance-masking, not performance-enhancing.

And for this drug, a 32-year-old runner received six years.

Two easy routes exist here and I will avoid both. The first: to call the AIU harsh without noticing that four of the six years came not from the charge but from lying during the investigation. The second: to say the athlete should have been protected, when she herself erased the defence the rules gave her.

What survives is this: the enforcement frontier has moved. The question is no longer "was the substance in the body" but "is the paper real." Across East African road-racing cases the pattern repeats — an initial substance violation, then a fabricated document built to explain it. And when one informal medical network serves many athletes in the same training cluster, cases like this stay queued in the pipeline.

The career mathematics

Age 32. A six-year ban from 10 September. Return age, roughly 38.

In Ethiopia a 2:18 woman is not selected automatically — several faster runners stand ahead of her. For a 38-year-old with a doping record and a chronic knee problem, the national selection door is shut. The club and agent system will read it the same way.

So the ban is six years on paper and a career's end in practice.

What to watch next

The next time an Ethiopian or Kenyan road racer withdraws from a race citing a knee or ankle injury, the question should not be whether the injury is real. The question should be whether a credentialed team physician is attached, and where the TUE file is.

The day road-racing agents start answering that question is the day cases like this decline. Until then, the clinics stay empty and the prescriptions keep getting forged.